Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by Freedom Capital

Sionna Therapeutics (NASDAQ:SION) was downgraded by analysts at Freedom Capital from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently commented on SION. Citigroup initiated coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. JonesTrading increased their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Citizens Jmp started coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price target for the company. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Finally, Wedbush started coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.22.

Sionna Therapeutics Stock Performance

NASDAQ:SION opened at $39.50 on Wednesday. Sionna Therapeutics has a one year low of $12.42 and a one year high of $48.44. The stock has a market cap of $1.78 billion, a PE ratio of -20.47 and a beta of 1.35. The stock has a 50 day moving average price of $39.56 and a 200 day moving average price of $39.56.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, analysts predict that Sionna Therapeutics will post -2.57 earnings per share for the current fiscal year.

Insider Activity at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 235,863 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,717,760 shares of company stock valued at $77,562,902 over the last quarter. 3.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SION. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics during the third quarter worth $30,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics during the second quarter worth $31,000. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics during the fourth quarter worth $36,000. Balyasny Asset Management L.P. purchased a new position in shares of Sionna Therapeutics during the fourth quarter worth $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Sionna Therapeutics during the fourth quarter worth $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.